Spontaneous thrombolysis: A forgotten determinant of life or death

Clinical and Applied Thrombosis/Hemostasis

Volumn 12, Issue 3, 2006, Pages 358-363

  Kovacs, Iren B ^a   Yamamoto, Junichiro ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Fibrinolysis; Platelets; Thrombolysis; Thrombosis

Indexed keywords

D DIMER; FIBRIN; FIBRIN DEGRADATION PRODUCT; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; PROTEIN C; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOPLASTY; ARTERY THROMBOSIS; BLOOD CLOT LYSIS; CORONARY ARTERY BLOOD FLOW; DEEP VEIN THROMBOSIS; FIBRINOLYSIS; GENETIC VARIABILITY; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HUMAN; LUNG EMBOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REPERFUSION; REVIEW; STROKE; THROMBOCYTE AGGREGATION; THROMBOELASTOGRAPHY; VASCULAR ENDOTHELIUM; VEIN THROMBOSIS;

ARTERIAL OCCLUSIVE DISEASES; BLOOD PLATELETS; FIBRINOLYSIS; HUMANS; REPERFUSION; THROMBOSIS;

EID: 33748743280     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029606291410     Document Type: Review

References (60)

1. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003;349:733.
2. Dalby M, Bouzamondo A, Lechar P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: A meta-analysis. Circulation 2003;108:1768.
3. DeWood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980;303:897.
4. Sanborn TA, Faxon DP, Kellett MA, Ryan TJ. Serial angiographic evidence of rapid resolution of coronary artery stenosis. Chest 1983;84:302.
5. Zingerman LS, Golikov AP, Topchiian GS, et al. The possibility of spontaneous lysis of a coronary thrombus patients with acute myocardial infarct. Kardioologiia 1988;28:24.
6. Christian TF, Milavetz JJ, Miller TD, et al. Prevalence of spontaneous reperfusion and associated myocardial salvage in patients with acute myocardial infarction. Am Heart J 1998;135:421.
7. Lee CW, Hong MK, Lee JH, et al. Determinants and prognostic significance of spontaneous coronary recanalization in acute myocardial infarction. Am J Cardiol 2001;87:951.
8. Seibert CE, Swanson WB. Lysis of thrombus in internal carotid artery in the neck. Report of a case. Acta Radiol Suppl 1976;347:271.
9. Engel HJ, Lichtlen P. Indications for a spontaneous lysis in the human coronary system-coronary stenosis as a dynamic process? Verh Dtsch Ges Inn Med 1977;83:245.
10. Weiner MA, Sniderman KW, Sos TA, et al. Two cases of spontaneous lysis of arterial thrombi. Cardiovasc Intervent Radiol 1984;7:24.
11. Weber W, Hotker U, Schild H. Spontaneous arterial recanalization-a case report. Rontgenblatter 1989;42:172.
12. Ose KJ, Blebea J, Fowl RJ, Kempczinski RF. Spontaneous thrombolysis of native artery occlusions. Ann Vasc Surg 1993;7:463.
13. Calleja S, De La Vega V, Llaneza JM, et al. Spontaneous recanalization of acute internal carotid after occlusion. Ann Vasc Surg 2004;May 27-Epub, ahead of print.
14. Osterlund B, Andersson B, Haggmark S, et al. Myocardial ischemia induces coronary t-PA release in the pig. Acta Anaesthesiol Scand 2002;46:271.
15. Chen LE, Seaber AV, Urbaniak JR. Thrombosis and thrombolysis in crushed arteries with or without anastomosis: A new microvascular model. Reconstr Microsurg 1996;12:31.
16. Sironi L, Maria CA, Bellosta S, et al. Endogenous proteolytic activity in a rat model of spontaneous cerebral stroke. Brain Res 2003;974:184.
17. Swan HJ. Acute myocardial infarction: A failure of timely, spontaneous thrombolysis. J Am Coll Cardiol 1989;13:1435.
18. Montaner J, Ribo M, Monasterio J, et al. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003;34:1038.
19. Johansson L, Jansson JH, Roman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000;31:26.
20. Schini-Kerth VB. Vascular biosynthesis of nitric oxide: Effect on hemostasis and fibrinolysis. Transfus Clin Biol 1999;6:355.
21. Rosenhek R, Korschineck I, Gharehbaghi-Schnell E, et al. Fibrinolytic balance of the arterial wall: Pulmonary artery displays increased fibrinolytic potential compared with aorta. Lab Invest 2003;83:871.
22. Zeng B, Bruce D, Kril J, et al. Influence of plasminogen deficiency on the contribution of polymorphonuclear leucocytes to fibrin/ogenolysis: Studies in plasminogen knock-out mice. Thromb Haemost 2002;88:805.
23. Burnand KG, Gaffney PJ, McGuinness CL, et al. The role of the monocyte in the generation and dissolution of arterial and venous thrombi. Cardiovasc Surg 1998;6:119.
24. Taylor FB Jr, Lockhart MS. Whole blood clot lysis: In vitro modulation by activated protein C. Thromb Res 1985;37:639.
25. Wun TC, Capuano A. Spontaneous fibrinolysis in whole human plasma. Identification of tissue activator-related protein as the major plasminogen activator causing spontaneous activity in vitro. J Biol Chem 1985;260:5061.
26. Glassman A, Abram M, Baxter G, Swett A. Euglobulin lysis times: An update. Ann Clin Lab Sci 1993;23:329.
27. Boudjeltia KZ, Cauchie P, Remacle C, et al. M. A new device for measurement of fibrin clot lysis: Application for the Euglobulin Clot Lysis Time. BMC Biotechnol 2002;2:8.
28. Stringer HAR, van Swieten P, Eijnen HFG, et al. Plasminogen activator inhibitor-1 released from activated platelets playas key role in thrombolysis resistance. Arterioscler Thromb 1994;14:1452.
29. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003;1:1566.
30. Soeki T, Tamura Y, Shinohara H, et al. Plasma concentrations of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction or sudden cardiac death. Int J Cardiol 2002;85:277.
31. Jansson JH, Olofsson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. Circulation 1993:2030.
32. Geppert A, Graf S, Beckmann R, et al. Concentration of endogenous tPA antigen in coronary artery disease: Relation to thrombotic events, aspirin treatment, hyperlipidemia, and multivessel disease. Arteriosder Thromb Vasc Biol 1998;18:1634.
33. Ver Elst K, Jochmans K, De Pauw A, De Waele M. Plasma D-dimer concentrations in different clinical conditions. Acta Clin Belg 2002;57:325.
34. Jang IK, Gold HK, Ziskind AA, et al. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator. Circulation 1989;79:920.
35. Niessen F, Hilger T, Hoehn M, Hossmann KA. Differences in clot preparation determine outcome of recombinant tissue plasminogen activator treatment in experimental thromboembolic stroke. Stroke 2003;34:2019.
36. Torr-Brown SR, Sobel BE. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets. Thromb Res 1993;72:413.
37. Robbie LA, Bennett B, Croll AM, et al. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost 1996;75:127.
38. Fay WP, Murphy JG, Owen WG. High concentrations of active plasminogen activator inhibitor in porcine coronary artery thrombi. Arterioscler Thromb Vasc Biol 1996;16:1277.
39. Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003;101:4844.
40. Moir E, Booth NA, Bennett B, Robbie LA. Polymorphonuclear leucocytes mediate endogenous thrombus lysis via a u-PA-dependent mechanism. Br J Haematol 2001;113:72.
41. Sobel BE. Fibrinolysis and diabetes. Front Biosci 2003;8:d1085.
42. Gveric D, Herrera B, Petzold A, et al. Impaired fibrinolysis in multiple sclerosis: A role for tissue plasminogen activator inhibitors. Brain 2003;126(Pt 7):1590.
43. Levi M, Keller TT, van Gorp E, ten Cate H. Infection and inflammation and the coagulation system. Cardiovasc Res 2003;60:26.
44. Colcci M, Binetti BM, Branca MG, et al. Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis. Hepatology 2003;38:230.
45. Libby P. Metformin and vascular protection: A cardiologist's view. Diabetes Metab 2003;29(4 Pt 2):6S117.
46. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opin 2003;19:540.
47. Ganotakis ES, Papadakis JA, Vrentzos GE, Mikhailidis DP. The effect of antihypertensive therapy on haemostatic parameters. Curr Pharm Des 2003;9:2445.
48. Madsen JS, Kristensen SR, Gram J, et al. Positive impact of hormone replacement therapy on the fibrinolytic system: A long-term randomised controlled study in healthy postmenopausal women. J Thromb Haemost 2003;1:1984.
49. Hilberg T, Prasa D, Sturzebecher J, et al. Blood coagulation and fibrinolysis after extreme short-term exercise. Thromb Res 2003;109:271.
50. Pedersen OD, Gram J, Jespersen J. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease. Thromb Haemost 1995;73:835.
51. Kwaan HC, Nabhan C. Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. Hematol Oncol Clin North Am 2003;17:103.
52. Juhan-Vague I, Morange PE, Aubert H, et al. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol 2002;22:867.
53. Lijnen HR. Gene targeting in hemostasis. Alpha2-antiplasmin. Front Biosci 2001;6:D239.
54. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 gene: Relationship to plasma PAI-1 levels in venous thromboembolism. Thromb Haemost 1998;79:975.
55. Dossenbach-Glaninger A, van Trotsenburg M, Dossenbach M, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and coagulation factor XIII Va134Leu polymorphism: Impaired fibrinolysis and early pregnancy loss. Clin Chem 2003;49:1081.
56. Hoekstra T, Geleijnse JM, Kluft C, et al. 4G/4G Genotype of PAI-1 gene is associated with reduced risk of stroke in elderly. Stroke 2003;Nov 6.
57. Yamamoto J, Yamashita T, Ikarugi H, et al. Gorog Thrombosis Test: A global in vitro test of platelet function and thrombolysis. Blood Coag Fibrinolysis 2003;14:31.
58. Yamamoto J, Kovacs IB. Shear-induced in vitro haemostasis/thrombosis tests: The benefit of using native blood. Blood Coagul Fibrinolysis 2003;14:697.
59. Ikarugi H, Yamashita T, Aoki R, et al. Impaired spontaneous thrombolytic activity in elderly and in habitual smokers, as measured by a new global thrombosis test. Blood Coagul Fibrinolysis 2003;14:781.
60. Yamashita T, Sato A, Ikarugi H, et al. Significantly reduced spontaneous thrombolytic activity in elderly men: A possible explanation for gender differences in risk of acute coronary syndromes. Thromb Res 2005;116:127.